Innophos Holdings (Innophos Holdings) ROCE % : 7.01% (As of Sep. 2019)

View and export this data going back to 2006. Start your Free Trial

What is Innophos Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Innophos Holdings's annualized ROCE % for the quarter that ended in Sep. 2019 was 7.01%.

Innophos Holdings ROCE % Historical Data

The historical data trend for Innophos Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innophos Holdings ROCE % Chart

Innophos Holdings Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

ROCE %

Get a 7-Day Free Trial

15.52

7.84

13.90

10.39

8.31

Innophos Holdings Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
ROCE %	Get a 7-Day Free Trial															8.58	6.77	8.82	8.10	7.01

Innophos Holdings ROCE % Calculation

Innophos Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	56.4	/	( ( (785.169 - 113.533)	+	(815.154 - 130) )	/ 2 )
	=	56.4	/	( (671.636	+	685.154)	/ 2 )
	=	56.4	/	678.395
	=	8.31 %

Innophos Holdings's ROCE % of for the quarter that ended in Sep. 2019 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2019 )		(Q: Jun. 2019 )		(Q: Sep. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2019 )		(Q: Jun. 2019 )		(Q: Sep. 2019 )
	=	52.948	/	( ( (870.155 - 119.29)	+	(875.844 - 116.505) )	/ 2 )
	=	52.948	/	( ( 750.865	+	759.339 )	/ 2 )
	=	52.948	/	755.102
	=	7.01 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

Innophos Holdings (NAS:IPHS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Innophos Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Innophos Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Innophos Holdings (Innophos Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Innophos Holdings Inc (NAS:IPHS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

259 Prospect Plains Road, Cranbury, NJ, USA, 08512

Website

http://www.innophos.com

Innophos Holdings Inc is a holding company that manufactures and sells through its subsidiaries a variety of ingredients used in the production of food, beverages, dietary supplements, pharmaceuticals, and oral care products. Innophos ingredients are made primarily from specialty phosphates. The company organizes itself into three segments namely Food, Health and Nutrition; Industrial Specialties and Other. The Food, Health and Nutrition segment contribute the maximum revenue. The company operates in U.S., Canada, Mexico and other countries.

Executives

John M Steitz	director	ALBEMARLE CORP, 451 FLORIDA ST, BATON ROUGE LA 70801
Kim Ann Mink	director, officer: Chairman, CEO, President	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
Gary A Cappeline	director	50 E RIVERCENTER BLVD, COVINGTON KY 41012
Karen R Osar	director	C/O WESTVACO CORP, ONE HIGH RIDGE PARK, STAMFORD CT 06905
Mark Santangelo	officer: Sr. VP, Mfg, Eng & EH&S	15710 JOHN F. KENNEDY BLVD., SUITE 300 HOUSTON TX 77032
Peter T Thomas	director	1000 LAKESIDE AVENUE, CLEVELAND OH 44114
Hermanus Kieftenbeld	officer: Senior VP and CFO	259 PROSPECT PLAINS RD., BLDG A, CRANBURY NJ 08512
James P. Zallie	director	5 WESTBROOK CORPORATE CENTER, WESTCHESTER IL 60154
Randy Gress	director, officer: CEO	259 PROSPECT PLAINS ROAD, P O BOX 8000, CRANBURY NJ 08512-8000
Stephen M Zide	director	BAIN CAPITAL PARTNERS, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Richard Heyse	officer: VP-Chief Financial Officer	259 PROSPECT PLAINS ROAD, BUILDING G, P O BOX 8000, CRANBURY NJ 08512-8000
Bain Capital Investors Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Partners Vii Lp	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Llc	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Fund Vii Lp	10 percent owner	JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116